Literature DB >> 22189152

Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy.

Lucy Garvey1, Veena Surendrakumar, Alan Winston.   

Abstract

BACKGROUND: Few studies investigating the rate of neurocognitive (NC) impairment in effectively treated neuro-asymptomatic HIV-infected subjects have been performed.
METHODS: We assessed NC function via a computerized cognitive test in HIV-infected subjects on stable combination antiretroviral therapy (cART) with plasma HIV RNA<50 copies/mL for at least 3 months. Neurologically symptomatic subjects were excluded. Current cART was evaluated for drug class (protease inhibitor [PI]- vs non-nucleoside reverse transcriptase inhibitor [NNRTI]-based) and Clinical Penetration Effectiveness (CPE) score. NC impairment was defined as a NC domain score>1 SD below mean age-matched population scores in at least 2 cognitive domains and global NC composite z-score calculated. Associations between NC scores and clinical parameters were evaluated using linear regression.
RESULTS: 101 (88% male) subjects participated. Median (IQR) age was 53 (43-62) years, with current CD4+ 525 (373-710) and nadir CD4+ 185 (83-260) cells/µL. 25 subjects (25%) had chronic hepatitis C. Median (IQR) CPE score was 1.5 (1.5-2.5), and 53% were receiving NNRTI-based cART. Overall 19 (19%) subjects had NC impairment. No association between presence of NC impairment and clinical parameters were observed (P>.14, all values). Poorer global NC composite z-score was independently associated with lower nadir CD4+ lymphocyte count (P=.04) and older age (P<.001) but not other study parameters (P>.10 all values).
CONCLUSION: In neuro-asymptomatic HIV-infected adults on stable cART, rates of NC impairment are low. HIV disease status (lower nadir CD4+ count) and older age, but not CPE score or cART drug class, are associated with poorer NC performance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22189152     DOI: 10.1310/hct1206-333

Source DB:  PubMed          Journal:  HIV Clin Trials        ISSN: 1528-4336


  31 in total

1.  Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics.

Authors:  Michael J Peluso; Serena Spudich
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

2.  Pattern of neurocognitive function in patients receiving boosted protease inhibitor monotherapy: a detailed neuropsychological study.

Authors:  Alicia González-Baeza; Fernando Carvajal; Carmen Bayón; Ignacio Pérez-Valero; Miriam Estébanez; Jose I Bernardino; Susana Monge; María Lagarde; Asunción Hernando; Francisco Arnalich; José R Arribas
Journal:  J Neurovirol       Date:  2014-04-24       Impact factor: 2.643

3.  Early viral suppression improves neurocognitive outcomes in HIV-infected children.

Authors:  Claudia S Crowell; Yanling Huo; Katherine Tassiopoulos; Kathleen M Malee; Ram Yogev; Rohan Hazra; Richard M Rutstein; Sharon L Nichols; Renee A Smith; Paige L Williams; James Oleske; William J Muller
Journal:  AIDS       Date:  2015-01-28       Impact factor: 4.177

Review 4.  Monitoring HIV-Associated Neurocognitive Disorder Using Screenings: a Critical Review Including Guidelines for Clinical and Research Use.

Authors:  Jody Kamminga; Luxshimi Lal; Edwina J Wright; Mark Bloch; Bruce J Brew; Lucette A Cysique
Journal:  Curr HIV/AIDS Rep       Date:  2017-06       Impact factor: 5.071

5.  Cross-sectional study of unexplained white matter lesions in HIV positive individuals undergoing brain magnetic resonance imaging.

Authors:  Lewis J Haddow; Cristina Dudau; Hoskote Chandrashekar; Jonathan D Cartledge; Harpreet Hyare; Robert F Miller; H Rolf Jäger
Journal:  AIDS Patient Care STDS       Date:  2014-05-01       Impact factor: 5.078

6.  Effects of comorbidity burden and age on brain integrity in HIV.

Authors:  Rowan Saloner; Robert K Heaton; Laura M Campbell; Anna Chen; Donald Franklin; Ronald J Ellis; Ann C Collier; Christina Marra; David B Clifford; Benjamin Gelman; Ned Sacktor; Susan Morgello; J Allen McCutchan; Scott Letendre; Igor Grant; Christine Fennema-Notestine
Journal:  AIDS       Date:  2019-06-01       Impact factor: 4.177

Review 7.  PET brain imaging in HIV-associated neurocognitive disorders (HAND) in the era of combination antiretroviral therapy.

Authors:  Jaime H Vera; Basil Ridha; Yvonne Gilleece; Aliza Amlani; Patrick Thorburn; Sabina Dizdarevic
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-01-05       Impact factor: 9.236

8.  Relationship of plasma cytokines and clinical biomarkers to memory performance in HIV.

Authors:  Stephen Correia; Ronald Cohen; Assawin Gongvatana; Skye Ross; James Olchowski; Kathryn Devlin; Karen Tashima; Bradford Navia; Suzanne Delamonte
Journal:  J Neuroimmunol       Date:  2013-09-27       Impact factor: 3.478

Review 9.  Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system.

Authors:  Andrea Calcagno; Giovanni Di Perri; Stefano Bonora
Journal:  Clin Pharmacokinet       Date:  2014-10       Impact factor: 6.447

10.  Exosomal MicroRNAs Associate With Neuropsychological Performance in Individuals With HIV Infection on Antiretroviral Therapy.

Authors:  Tess OʼMeara; Yong Kong; Jennifer Chiarella; Richard W Price; Rabib Chaudhury; Xinran Liu; Serena Spudich; Kevin Robertson; Brinda Emu; Lingeng Lu
Journal:  J Acquir Immune Defic Syndr       Date:  2019-12-15       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.